Picato® Gel Receives EU Marketing Authorisation for Treatment of Actinic Keratosis

Picato® Gel Receives EU Marketing Authorisation for Treatment of Actinic Keratosis PR Newswire BALLERUP, Denmark, November 19, 2012 BALLERUP, Denmark, November 19, 2012 /PRNewswire/ -- ®Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato ®(ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato gel is a once-daily, two or three day field-directed topical treatment for actinic keratosis, a common skin condition which if not treated can lead [1]to squamous cell carcinoma, a form of non-melanoma skin cancer. To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/prne/leo-pharma/58649/ (Logo: http://www.newscom.com/cgi-bin/prnh/20110606/460992 ) [2]Actinic keratosis can be an under-diagnosed condition, yet the prevalence in adults aged over 40 years ranges between 11-25 per cent in susceptible populations of the northern hemisphere, and between 40-60 per cent in the [3]southern hemisphere. Current topical treatments have long treatment durations that last for periods from one, up to [4-6]four months, which can lead to low patient adherence.